In Reference To: Tian S, Switchenko JM, Buchwald ZS, et al. Lung Stereotactic Body Radiation Therapy and Concurrent Immunotherapy: A Multicenter Safety and Toxicity Analysis. Int J Radiat Oncol Biol Phys. 2020;108(1):304-313. Read more

A significant proportion of patients with stage I to III NSCLC or SCLC will have locoregional or distant metastases following curative-intent therapy. Studies have reported local recurrence rates of 22% […] Read more

For patients with metastatic lung cancer, frequent scans are a stark reality of living with cancer. Although most scans happen every 3 months, some clinical trials require scans more often […] Read more

Lung cancer remains the leading cause of cancer-related deaths.1 Advances in early detection of lung cancer following the implementation of screening programs and the availability of newer therapies have increased […] Read more

Surgery is considered the preferred treatment in patients with lung cancer who are fit to undergo the procedure. Stereotactic radiotherapy (SBRT) is guideline recommended for patients who are unfit for […] Read more

In Response To: Palma DA, Olson R, Harrow, S, et al. Stereotactic Ablative Radiotherapy for the Comprehensive Treatment of Oligometastatic Cancers: Long-Term Results of the SABR-COMET Phase II Randomized Trial. […] Read more

IN REFERENCE TO: Ladbury CJ, Rusthoven CG, Camidge DR, Kavanagh BD, Nath SK. Impact of radiation dose to the host immune system on tumor control and survival for stage III […] Read more

The recently published long-term results of the SABR-COMET phase II trial have further invigorated treatment options for patients with oligometastatic cancer.1 The early results of the SABR-COMET trial published in […] Read more

Megan Daly The standard of care for fit patients with unresectable, locally advanced (LA-) NSCLC is concurrent chemoradiation (CRT) followed by consolidation durvalumab. However, thoracic radiation (RT) for lung cancer […] Read more